Progress in Rehabilitation Medicine

Medication Burden and Its Escalation Predict Incidence of Hospital-associated Disability in Older Inpatients: A Prospective Cohort Study

Fig. 1. Subgroup analysis for development of HAD.
Open the figure at full size
Fig. 1. Subgroup analysis for development of HAD.Subgroup analysis for development of HAD.Kose et al.
Cohort study of 206 peoplePopulations

Multicentre

Follow

Abstract

OBJECTIVES: Whether medication burden contributes to hospital-associated disability (HAD) in older inpatients remains unclear. We investigated the relationship between medication count and HAD incidence to identify potential pharmacotherapy targets. METHODS: This multicenter prospective cohort study used data from a HAD registry collected from 1 February 2023 to 31 March 2025. Eligible patients were aged 70 years or older, admitted to medical wards, received rehabilitation, had hospital stays of 48 h or longer, and were independent in activities of daily living at admission (Katz Index of 6). HAD was defined as a Katz Index less than 6 at discharge. The primary outcome was medication count at admission; the secondary outcome was change in medication count during hospitalization. Multivariable logistic regression models with varying covariate adjustment assessed whether admission medication count and in-hospital change were independently associated with HAD. RESULTS: Among the 206 patients (mean age 80.3 years; 60.7% men), 60 (29.1%) developed HAD. Across the models, the medication counts on admission independently increased the HAD risk [odds ratio (OR), 1.14; 95% confidence interval (CI), 1.01-1.28]. Increased medication count during hospitalization was also associated with HAD development (OR, 1.21; 95% CI, 1.01-1.45), reaching significance in most models. Subgroup analyses showed that a medication count on admission of at least five or at least six increased the HAD risk (OR, 1.89 and 1.93, respectively). CONCLUSIONS: Both admission medication count and increase in the in-hospital medication count were associated with HAD development. To prevent HAD development, medication regimens should be optimized, including efforts to reduce unnecessary polypharmacy.